How new CST evidence and UK dementia care quality focus underscore the relevance and potential of Ayla - featuring Antony Hall, new Brain+ advisor
How does this Q&A work:
This company invites all interested, both current investors and potential investors to participate in this event, ask questions directly on this page before the event starts and upvote those questions you would like addressed.
The company will address as many questions as possible, and focus on those questions most wanted by investors.
Speakers at this event:
5 Questions
June 10, 2025
Hey again, can you please update us all on the current back-order book for UK ? the one that had a number of EUR 630.000 at the latest update.
June 9, 2025
If the danish cities wants to use Ayla, to role out and provide CST, to people with dementia, how fast can Brain+ deliver Ayla to these cities?
June 9, 2025
Hey B+ , Can you update investors in how the ongoing T05 issuance is going please. Guarantors + how many % of the nearly 6 mill kr is signed for after the first week ? By not guarantors only but normal comitted investors - regards
June 8, 2025
Have you with the past and recent contracts, and feedback, gained insight, on how much easier it is to role out or scale up CST treatment with Ayla, compared to other methods, used to role out or scale up CST treatment?
June 7, 2025
Can you point for point, tell what benifits of CST treatment the published reports showed, and how Ayla can assist the staff, in providing these benifits of CST treatment,to the patients?